Nanotech revolution for the Anti-Cancer drug delivery through Blood-Brain-Barrier

Current Cancer Drug Targets

Volumn 12, Issue 3, 2012, Pages 186-196

  Caraglia, M ^a   de Rosa, G ^b   Salzano, G ^b   Santini, D ^c   Lamberti, M ^d   Sperlongano, P ^a   Lombardi, A ^a   Abbruzzese, A ^a   Addeo, R ^e  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d Dipartimento di Sanita Pubblica   (Italy)

^e S Giovanni di Dio Hospital   (Italy)

Author keywords

Brain delivery; Drug delivery; Drug targeting; Liposomes; Nanoparticles; Tumour

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ALBUMIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHITOSAN; CREMOPHOR; CYTOTOXIC AGENT; DOXORUBICIN; FOLIC ACID; IRINOTECAN; LIPOSOME; MACROGOL DERIVATIVE; METHOXYPOLYETHYLENE GLYCOL; MONOCLONAL ANTIBODY; NANOCARRIER; NANOPARTICLE; PHARMACOLOGICAL BIOMARKER; PHOSPHOLIPID; POLYGLACTIN; POLYLACTIDE; POLYMER; PROTEIN KINASE INHIBITOR; SOLID LIPID NANOPARTICLE; TAXANE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; ZOLEDRONIC ACID;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; BRAIN; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CELL PROLIFERATION; CELL SURVIVAL; CEREBROSPINAL FLUID; CHIMERA; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RELEASE; DRUG RETENTION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; ENHANCED PERMEABILITY AND RETENTION; ERYTHEMA; ERYTHEMA MULTIFORME; EXTRAVASATION; HAND FOOT SYNDROME; HISTOCHEMISTRY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KAPOSI SARCOMA; LIPOSOMAL DELIVERY; METASTATIC BREAST CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; NAIL DISEASE; NANOENCAPSULATION; NANOTECHNOLOGY; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PHARMACODYNAMICS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN TOXICITY; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS;

EID: 84857130085     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912799277421     Document Type: Review

References (104)

1. Cheong, I.; Huang, X.; Thornton, K.; Diaz, L. A.; Zhou, S. Targeting cancer with bugs and liposomes: Ready, aim, fire. Cancer Res. 2007, 67, 9605-9608.
2. Wyatt, A. J.; Leonard, G. D.; Sachs, D. L. Cutaneous reactions to chemotherapy and their management. Am. J. Clin. Dermatol. 2006, 7, 45-63.
3. DeJonge, M. J. A.; Sparreboom, A.; Verweij, J. The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies. Cancer Treat. Rev. 1998, 24, 205-220.
4. Iyer, L.; King, C. D.; Whitington, P. F.; Green, M. D.; Tephly, T. R.; Coffman, B. L.; Ratain, M. J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridinediphosphateglucuronosyltransferase isoform1A1 in the glucuronidation of its active metabolite (SN-28) in human liver microsomes. J. Clin. Invest. 1998, 101, 847-854.
5. Atyabi, F.; Farkhondehfai, A.; Esmaeili, F.; Dinarvand, R. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice. Acta Pharm. 2009, 59, 133-144.
6. O'Brien, M. E.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D. G.; Tomczak, P.; Ackland, S. P.; Orlandi, F.; Mellars, L.; Alland, L.; Tendler, C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15, 440-449.
7. Gabizon, A. A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001, 19, 424-436.
8. Allen, T. M.; Cullis, P.R. Drug delivery systems: Entering the mainstream. Science 2004, 303, 1818-1822.
9. Fleisch, H. Development of bisphosphonates. Breast Cancer Res. 2002, 4, 30-34.
10. Green, J. R. Antitumor effects of bisphosphonates. Cancer 2003, 97, 840-847.
11. Soma, M. R.; Corsini, A.; Paoletti, R. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol. Lett. 1992, 64-65.
12. Rogers, M. J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 2003, 9, 2643-2658.
13. Rogers, M. J. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif. Tissue Int. 2004, 75, 451-461.
14. Reid, T. S.; Terry, K. L.; Casey, P. J.; Beese, L. S. Crystallographic analysis of CaaXprenyltransferases complexed with substrates defines rules of protein substrate selectivity. J. Mol. Biol. 2004, 343, 417-433.
15. Santini, D.; Caraglia, M.; Vincenzi, B.; Holen, I.; Scarpa, S.; Budillon, A.; Tonini, G. Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat. Clin. Pract. Oncol. 2006, 3, 325-338.
16. Caraglia, M.; D'Alessandro, A. M.; Marra, M.; Giuberti, G.; Vitale, G.; Viscomi, C.; Colao, A.; Prete, S. D.; Tagliaferri, P.; Tassone, P.; Budillon, A.; Venuta, S.; Abbruzzese, A. The farnesyltransferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 2004, 23, 6900-6913.
17. Caraglia, M.; Marra, M.; Leonetti, C.; Meo, G.; D'Alessandro, A. M.; Baldi, A.; Santini, D.; Tonini, G.; Bertieri, R.; Zupi, G.; Budillon, A.; Abbruzzese, A. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J. Cell. Physiol. 2007, 211, 533-543.
18. Caraglia, M.; Santini, D.; Marra, M.; Vincenzi, B.; Tonini, G.; Budillon, A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr. Relat. Cancer 2006, 13, 7-26.
19. Caraglia, M.; Marra, M.; Naviglio, S.; Botti, G.; Addeo, R.; Abbruzzese, A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin. Pharmacother. 2010, 11, 141-154.
20. Weiss, H. M.; Pfaar, U.; Schweitzer, A.; Wiegand, H.; Skerjanec, A.; Schran, H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab. Dispos. 2008, 36, 2043-2049.
21. Marra, M.; Salzano, G.; Leonetti, C.; Tassone, P.; Scarsella, M.; Zappavigna, S.; Calimeri, T.; Franco, R.; Liguori, G.; Cigliana, G.; Ascani, R.; La Rotonda, M. I.; Abbruzzese, A.; Tagliaferri, P.; Caraglia, M.; De Rosa, G. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine 2011, 6, 955-64
22. Salzano, G.; Marra, M.; Leonetti, C.; Porru, M.; Zappavigna S.; Abbruzzese, A.; La Rotonda, M. I.; Caraglia, M.; De Rosa, G. Nanotechnology to use zoledronic acid as a potent antitumoral agent. J. Drug Deliv. Sci. Technol., in press.
23. Shmeeda, H.; Amitay, Y.; Gorin, J.; Tzemach, D.; Mak, L.; Ogorka, J.; Kumar, S.; Zhang, J. A.; Gabizon, A. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J. Control. Release 2010, 146, 76-83.
24. Brightman, M. W.; Reese, T. S. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 1969, 40, 648-677.
25. Reese, T. S.; Karnovsky, M. J. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 1967, 34, 207-217.
26. Bodor, N.; Buchwald, P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev. 1999, 36, 229-254.
27. Laterra, J.; Guerin, C.; Goldstein, G. W. Astrocytes induce neural microvascular endothelial cells to form capillary-like structures in vitro. J. Cell Physiol. 1990, 144, 204-215.
28. Tao-Cheng, J. H.; Nagy, Z.; Brightman, M. W. Tight junctions of brain endothelium in vitro are enhanced by astroglia. J. Neurosci. 1987, 7, 3293-3299.
29. Gu, J. G.; Nath, A.; Geiger, J. D. Characterization of inhibitor-sensitive and -resistant adenosine transporters in cultured human fetal astrocytes. J. Neurochem. 1996, 67, 972-977.
30. Decleves, X.; Regina, A.; Laplanche, J. L.; Roux, F.; Boval, B.; Launay, J. M.; Scherrmann, J. M. Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes. J. Neurosci. Res. 2000, 60, 594-601.
31. Pardridge, W. M. Drug delivery to the brain. J. Cereb. Blood Flow Metab. 1997, 17, 713-731.
32. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65, 271-284.
33. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J. W.; Thurston, G.; Roberge, S.; Jain, R. K.; McDonald, D. M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 156, 1363-1380.
34. Hobbs, S. K.; Monsky, W. L.; Yuan, F.; Roberts, G.; Griffith, L.; Torchilin, V. P.; Jain, R. K. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4607-4612.
35. Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D. A.; Torchilin, V. P.; Jain, R. K. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res. 1995, 55, 3752- 3756.
36. Jain, R. K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990, 9, 253-266.
37. Jain, R. K.; Carmeliet, P. F. Vessels of death or life. Sci. Am. 2001, 285, 38-45.
38. Jain R. K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987, 6, 559-593.
39. Schiffelers, R. M.; Storm, G.; Bakker-Woudenberg, I. A. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm. Res. 2001, 18, 780-787.
40. Edens, H. A.; Levi, B. P.; Jaye, D. L.; Walsh, S.; Reaves, T. A.; Turner, J. R.; Nusrat, A.; Parkos, C. A. Neutrophil transepithelial migration: evidence for sequential, contact-dependent signaling events and enhanced paracellular permeability independent of transjunctional migration. J. Immunol. 2002, 169, 476-486.
41. Allen, T. M.; Hansen, C.; Rutledge, J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta 1989, 981, 27-35.
42. Gabizon, A.; Papahadjopoulos, D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 6949-6953.
43. Allen, T. M.; Hansen, C.; Martin, F.; Redemann, C.; Yau-Young, A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991, 1066, 29-36.
44. Papahadjopoulos, D.; Allen, T. M.; Gabizon, A.; Mayhew, E.; Matthay, K.; Huang, S. K.; Lee, K. D.; Woodle, M. C.; Lasic, D. D.; Redemann, C. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 11460-11464.
45. Huwyler, J.; Wu, D.; Pardridge, W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 14164-14169.
46. Siegal, T.; Horowitz, A.; Gabizon, A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 1995, 83, 1029-1037.
47. Schmidt, J.; Metselaar, J. M.; Wauben, M. H.; Toyka, K. V.; Storm, G.; Gold, R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003, 126, 1895-1904.
48. Abbruzzese, A.; De Rosa, G.; Luongo, L.; Maione, S.; Marra, M.; Caraglia, M.; Palazzo, E.; Rossi, F.; Salzano, G.; De Novellis, V. Uso di bisfosfonati per la preparazione di formulazioni farmaceutiche per il trattamento dei sintomi associati a dolore neuropatico. NA2010A000046, September 28, 2010.
49. Arnold, R. D.; Mager, D. E.; Slack, J. E.; Straubinger, R. M. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin. Cancer Res. 2005, 11, 8856-8865.
50. Caraglia, M.; Addeo, R.; Costanzo, R.; Montella, L.; Faiola, V.; Marra, M.; Abruzzese, A.; Palmieri, G.; Budillon, A.; Grillane, F.; Venuta, S.; Tagliaferro, P.; Del Prete, S. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother. Pharmacol. 2006, 57, 34-9
51. Zara, G. P.; Cavalli, R.; Bargoni, A.; Fundaro, A.; Vighetto, D.; Gasco, M. R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target 2002, 10, 327-335.
52. Koziara, J. M.; Lockman, P. R.; Allen, D. D.; Mumper, R. J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Release 2004, 99, 259-269.
53. Brigger, I.; Morizet, J.; Aubert, G.; Chacun, H.; Terrier-Lacombe, M. J.; Couvreur, P.; Vassal, G. Poly(ethylene glycol)-coated hexadecylcyanoacrylatenanospheres display a combined effect for brain tumor targeting. J. Pharmacol. Exp. Ther. 2002, 303, 928-936.
54. Calvo, P.; Gouritin, B.; Brigger, I.; Lasmezas, C.; Deslys, J.; Williams, A.; Andreux, J. P.; Dormont, D.; Couvreur, P. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J. Neurosci. Methods 2001, 111, 151-155.
55. Kim, H. R.; Andrieux, K.; Delomenie, C.; Chacun, H.; Appel, M.; Desmaele, D.; Taran, F.; Georgin, D.; Couvreur, P.; Taverna, M. Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis 2007, 28, 2252-2261.
56. Garcia-Garcia, E.; Gil, S.; Andrieux, K.; Desmaele, D.; Nicolas, V.; Taran, F.; Georgin, D.; Andreux, J. P.; Roux, F.; Couvreur, P. A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. Cell Mol. Life Sci. 2005, 62, 1400-1408.
57. Kim, H. R.; Gil, S.; Andrieux, K.; Nicolas, V.; Appel, M.; Chacun, H.; Desmaele, D.; Taran, F.; Georgin, D.; Couvreur, P. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol. Life Sci. 2007, 64, 356-364.
58. Kim, H. R.; Andrieux, K.; Gil, S.; Taverna, M.; Chacun, H.; Desmaele, D.; Taran, F.; Georgin, D.; Couvreur, P. Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 2007, 8, 793-799.
59. Calvo, P.; Gouritin, B.; Chacun, H.; Desmaele, D.; d'Angelo, J.; Noel, J. P.; Georgin, D.; Fattal, E.; Andreux, J. P.; Couvreur, P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 2001, 18, 1157-1166.
60. Kreuter, J.; Alyautdin, R. N.; Kharkevich, D. A.; Ivanov, A. A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995, 674, 171-174.
61. Alyautdin, R. N.; Petrov, V. E.; Langer, K.; Berthold, A.; Kharkevich, D. A.; Kreuter, J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 1997, 14, 325-328.
62. Alyautdin, R. N.; Tezikov, E. B.; Ramge, P.; Kharkevich, D. A.; Begley, D. J.; Kreuter, J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsul. 1998, 15, 67-74.
63. Petri, B.; Bootz, A.; Khalansky, A.; Hekmatara, T.; Muller, R.; Uhl, R.; Kreuter, J.; Gelperina, S. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J. Control. Release 2007, 117, 51-58.
64. Tian, X. H.; Lin, X. N.; Wei, F.; Feng, W.; Huang, Z. C.; Wang, P.; Ren, L.; Diao, Y. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int. J. Nanomedicine 2011, 6, 445-452,
65. Kreuter, J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J. Nanosci. Nanotechnol. 2004, 4, 484-488.
66. Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; Alyautdin, R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target 2002, 10, 317-325.
67. Gao, K.; Jiang, X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 2006, 310, 213-219.
68. Tahara, K.; Miyazaki, Y.; Kawashima, Y.; Kreuter, J.; Yamamoto, H. Brain targeting with surface-modified poly(d,l-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur. J. Pharm. Biopharm. 2011, 77, 1, 84-88.
69. Gelperina, S.; Maksimenko, O.; Khalansky, A.; Vanchugova, L.; Shipulo, E.; Abbasova, K.; Berdiev, R.; Wohlfart, S.; Chepurnova, N.; Kreuter, J. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur. J. Pharm. Biopharm. 2010, 74, 157-163.
70. Kulkarni, S. A.; Feng, S. S. Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier. Nanomedicine(Lond.) 2011, 6, 377-394.
71. Wohlfart, S.; Khalansky, A. S.; Gelperina, S.; Maksimenko, O.; Bernreuther, C.; Glatzel, M.; Kreuter, J. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS ONE 2011, 6, 19121.
72. Tsuji, A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx. 2005, 2, 54-62.
73. Qutub, A. A.; Hunt, C. A. Glucose transport to the brain: a systems model. Brain Res. Brain Res. Rev. 2005, 49, 595-617.
74. Schubert, D. Glucose metabolism and Alzheimer's disease. Ageing Res. Rev. 2005, 4, 240-257.
75. Dick, A. P.; Harik, S. I.; Klip, A.; Walker, D. M. Identification and characterization of the glucose transporter of the blood-brain barrier by cytochalasin B binding and immunological reactivity. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 7233-7237.
76. Umezawa, F.; Eto, Y. Liposome targeting to mouse brain: mannose as a recognition marker. Biochem. Biophys. Res. Commun.1988, 153, 1038-1044.
77. Qin, Y.; Fan, W.; Chen, H.; Yao, N.; Tang, W.; Tang, J.; Yuan, W.; Kuai, R.; Zhang, Z.; Wu, Y.; He, Q. In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J. Drug Target. 2010, 18, 536-549.
78. Dehouck, B.; Dehouck, M. P.; Fruchart, J. C.; Cecchelli, R. Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. J. Cell Biol. 1994, 126, 465-473.
79. Pardridge, W. M.; Eisenberg, J.; Yang, J. Human blood-brain barrier transferrin receptor. Metabolism 1987, 36, 892-895.
80. Pardridge, W. M. Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug Discov. 2002, 1, 131-139.
81. Leitner, D. F.; Connor, J. R. Functional roles of transferrin in the brain. Biochim. Biophys. Acta 2011 Nov 21.
82. Vyas, S. P.; Sihorkar, V. Endogenous carriers and ligands in non-immunogenic site-specific drug delivery. Adv. Drug Deliv. Rev. 2000, 43, 101-164.
83. Li, H.; Sun, H.; Qian, Z. M. The role of the transferrin-transferrin-receptor system in drug delivery and targeting. Trends Pharmacol. Sci. 2002, 23, 206-209.
84. Qian, Z. M.; Shen, X. Brain iron transport and neurodegeneration. Trends Mol. Med. 2001, 7, 103-108.
85. Soni, V.; Kohli, D. V.; Jain, S. K. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. J. Drug Target 2005, 13, 245-250.
86. Hatakeyama, H.; Akita, H.; Maruyama, K.; Suhara, T.; Harashima, H. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int. J. Pharm. 2004, 281, 25-33.
87. Kaili, H.; Yanbin, S.; Wenming, J.; Jiaying, H.; Shixian, H.; Xinguo, J. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson's disease. Int. J. Pharmaceutics. 2011, 415, 273-283.
88. Kreuter, J.; Hekmatara, T.; Dreis, S.; Vogel, T.; Gelperina, S.; Langer, K. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Control. Release 2007, 118, 54-58.
89. Zensi, A.; Begley, D.; Pontikis, C.; Legros, C.; Mihoreanu, L.; Wagner, S.; Buchel, C.; von, B.H.; Kreuter, J. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurons. J. Control. Release 2009, 137, 78-86.
90. Ulbrich, K.; Knobloch, T.; Kreuter, J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J. Drug Target 2011, 19(2), 125-32.
91. Bickel, U.; Kang, Y. S.; Yoshikawa, T.; Pardridge, W. M. In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J. Histochem. Cytochem.1994, 42, 1493-1497.
92. Pardridge, W. M.; Buciak, J. L.; Friden, P. M. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 1991, 259, 66-70.
93. Jefferies, W. A.; Brandon, M. R.; Hunt, S. V.; Williams, A. F.; Gatter, K. C.; Mason, D. Y. Transferrin receptor on endothelium of brain capillaries. Nature 1984, 312, 162-163.
94. Aktas, Y.; Yemisci, M.; Andrieux, K.; Gursoy, R. N.; Alonso, M. J.; Fernandez-Megia, E.; Novoa-Carballal, R.; Quinoa, E.; Riguera, R.; Sargon, M. F.; Celik, H. H.; Demir, A. S.; Hincal, A. A.; Dalkara, T.; Capan, Y.; Couvreur, P. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem. 2005, 16, 1503-1511.
95. Olivier, J. C.; Huertas, R.; Lee, H. J.; Calon, F.; Pardridge, W. M. Synthesis of pegylated immunonanoparticles. Pharm. Res. 2002, 19, 1137-1143.
96. Ulbrich, K.; Hekmatara, T.; Herbert, E.; Kreuter, J. Transferrin-and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 2009, 71, 251-256.
97. Cerletti, A.; Drewe, J.; Fricker, G.; Eberle, A. N.; Huwyler, J. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J. Drug Target 2000, 8, 435-446.
98. Shi, N.; Zhang, Y.; Zhu, C.; Boado, R. J.; Pardridge, W. M. Brain-specific expression of an exogenous gene after i.v.administration. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 12754-12759.
99. Zhang, Y.; Schlachetzki, F.; Pardridge, W. M. Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther. 2003, 7, 11-18.
100. Zhang, Y.; Schlachetzki, F.; Zhang, Y. F.; Boado, R. J.; Pardridge, W. M. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum. Gene Ther. 2004, 15, 339-350.
101. Costantino, L.; Gandolfi, F.; Tosi, G.; Rivasi, F.; Vandelli, M. A.; Forni, F. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Release 2005, 108, 84-96.
102. Tosi, G.; Costantino, L.; Rivasi, F.; Ruozi, B.; Leo, E.; Vergoni, A. V.; Tacchi, R.; Bertolini, A.; Vandelli, M. A.; Forni, F. Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J. Control. Release 2007, 122, 1-9.
103. Tosi, G.; Fano, R. A.; Bondioli, L.; Badiali, L.; Benassi, R.; Rivasi, F.; Ruozi, B.; Forni, F.; Vandelli, M. A. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine (Lond) 2011, 3, 423-36.
104. Tosi, G.; Vergoni, A. V.; Ruozi, B.; Bondioli, L.; Badiali, L.; Rivasi, F.; Costantino, L.; Forni, F.; Vandelli, M. A. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: in vivo pharmacological evidence and biodistribution. J. Control. Release 2010, 145, 49-57.